IBD女性孕期能不能吃药?队列研究告诉你答案
创作:Epi汪 审核:Epi汪 2020年12月04日
  • 纳入队列研究中1490名炎症性肠炎(IBD)孕妇,其中孕期服用巯嘌呤类药物的有242人,服用生物制剂的有642人,二者都使用的有227人,而都不使用的有379人;
  • 无论使用何种药物,胎儿先天畸形、自然流产、早产、低出生体重、感染等不良妊娠结局发生率均未增高;
  • 反之,IBD症状更为严重者,其发生自然流产及早产的风险增高;
  • 本研究提示,IBD女性在孕期可继续使用生物制剂或巯嘌呤类药物缓解症状,或可减少不良妊娠事件。
主编推荐语
Epi汪
炎症性肠炎是痛苦的,而炎症性肠炎的孕妇如果不能继续服药缓解症状,将更加痛苦。本研究通过队列研究观察性数据进行分析,发现孕期服用生物制剂或者巯嘌呤类药物并不会增加不良妊娠结局事件的发生率。这对未来制订IBD孕期治疗策略提供了良好的证据支持。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
Gastroenterology [IF:22.682]

Pregnancy and Neonatal Outcomes after Fetal Exposure To Biologics and Thiopurines among Women with Inflammatory Bowel Disease

具有炎症性肠炎的母亲其胎儿暴露于生物制剂或者巯嘌呤类药物对怀孕和新生儿结局的影响

10.1053/j.gastro.2020.11.038

2020-11-20, Article

Abstract & Authors:展开

Abstract:收起
Background: Pregnant women with inflammatory bowel disease (IBD) may require biologic or thiopurine therapy to control disease activity. Lack of safety data has led to therapy discontinuation during pregnancy with health repercussions to mother and child.
Methods: Between 2007 and 2019, pregnant women with IBD were enrolled in a prospective, observational, multicenter study across the United States. The primary analysis was a comparison of five outcomes (congenital malformations, spontaneous abortions, preterm birth, low birth weight (LBW) and infant infections) among pregnancies exposed versus unexposed in utero to biologics, thiopurines or a combination. Bivariate analyses followed by logistic regression models adjusted for relevant confounders were utilized to determine the independent effects of specific drug classes on outcomes of interest.
Results: Among 1490 completed pregnancies, there were 1431 live births. One-year infant outcomes were available in 1010. Exposure was to thiopurines (242), biologics (642) or both (227) versus unexposed (379). Drug exposure did not increase the rate of congenital malformations, spontaneous abortions, preterm birth, LBW, and infections over the first year of life. Higher disease activity was associated with risk of spontaneous abortion (HR 3.41, 95% CI 1.51-7.69) and preterm birth with increased infant infection (OR 1.73, 95% CI 1.19-2.51).
Conclusions: Biologic, thiopurine, or combination therapy exposure during pregnancy was not associated with increased adverse maternal or fetal outcomes at birth or within the first year of life. Therapy with these agents can be continued throughout pregnancy in women with IBD to maintain disease control and reduce pregnancy related adverse events

First Authors:
Uma Mahadevan

Correspondence Authors:
Uma Mahadevan

All Authors:
Uma Mahadevan,Millie D Long,Sunanda V Kane,Abhik Roy,Marla C Dubinsky,Bruce E Sands,Russell D Cohen,Christina D Chambers,William J Sandborn

评论